Johnson & Johnson (NYSE:JNJ) Stake Raised by RBO & Co. LLC

RBO & Co. LLC lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 213,574 shares of the company’s stock after purchasing an additional 1,654 shares during the quarter. Johnson & Johnson comprises approximately 5.0% of RBO & Co. LLC’s investment portfolio, making the stock its 4th biggest position. RBO & Co. LLC’s holdings in Johnson & Johnson were worth $30,887,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. IFS Advisors LLC boosted its position in shares of Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after purchasing an additional 100 shares during the period. WealthTrak Capital Management LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter worth $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at $29,000. Bay Harbor Wealth Management LLC purchased a new stake in shares of Johnson & Johnson in the 4th quarter valued at $32,000. Finally, Conquis Financial LLC acquired a new position in Johnson & Johnson during the 4th quarter worth about $33,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $155.90 on Wednesday. The stock has a market capitalization of $375.11 billion, a price-to-earnings ratio of 23.44, a PEG ratio of 2.56 and a beta of 0.49. The business’s 50 day moving average is $159.36 and its two-hundred day moving average is $154.77. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.34%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s payout ratio is currently 57.84%.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on JNJ shares. Guggenheim reiterated a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. The Goldman Sachs Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their target price for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Leerink Partners dropped their price target on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Finally, Benchmark upgraded Johnson & Johnson to a “strong-buy” rating in a research note on Thursday, April 24th. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $171.82.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.